A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies

BACKGROUND: Vaccine-associated anaphylaxis is a rare event (1.34 events/million doses; 0.00017% occurrence over 26 years). Several reports of allergic reactions concerning for anaphylaxis have been reported early into the Pfizer-BioNTech and Moderna coronavirus disease 2019 (COVID-19) vaccine campai...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaker, Marcus, Abrams, Elissa M., Greenhawt, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Academy of Allergy, Asthma & Immunology 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942189/
https://www.ncbi.nlm.nih.gov/pubmed/33711496
http://dx.doi.org/10.1016/j.jaip.2021.02.054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942189/
https://www.ncbi.nlm.nih.gov/pubmed/33711496
http://dx.doi.org/10.1016/j.jaip.2021.02.054

Ejemplares similares